top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hIL4/hIL4RA mice
Strain Name C57BL/6-Il4tm2(IL4)BcgenIl4ratm1(IL4RA)Bcgen/Bcgen Common Name  B-hIL4/hIL4RA  mice
Background C57BL/6 Catalog number 120551
Related Gene 

BCGF-1, BCGF1, BSF-1, BSF1, IL-4

CD124, IL-4RAA, IL4R

NCBI Gene ID
16189,16190



mRNA expression analysis


from clipboard


Strain specific analysis of IL4 and IL4RA gene expression in WT and B-hIL4/hIL4RA mice by RT-PCR. Mouse Il4 and Il4ra mRNA was detectable in splenocytes of wild-type (+/+) but not in homozygous B-hIL4/hIL4R mice (H/H) mice. Human IL4 and IL4RA mRNA was detectable only in homozygous B-hIL4/hIL4R mice but not in wild-type mice.


Protein expression analysis


from clipboard



Strain specific IL4 expression analysis in homozygous B-hIL4/hIL4RA mice by ELISA. Serum were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hIL4/hIL4RA mice (H/H) stimulated with anti-mouse CD3ε antibody (37.5 μg/mL, 200 μL/mouse, i.p.) for 1.5 hrs in vivo (female, 6-8 weeks old, n=3). Protein expression was analyzed with anti-mouse IL4 antibody (Biolegend, 431104) and anti-human IL4 antibody (Biolegend, 430307) by ELISA. Mouse IL4 was only detectable in wild-type C57BL/6 mice. Human IL4 was exclusively detectable in homozygous B-hIL4/hIL4RA mice, but not in wild-type C57BL/6 mice.



Protein expression analysis


from clipboard


Strain specific IL4RA expression analysis in homozygous B-hIL4/hIL4RA mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hIL4/hIL4RA mice (H/H) stimulated with anti-mouse CD3ε antibody (37.5 μg/mL, 200 μL/mouse, i.p.) for 1.5 hrs in vivo (female, 8-week-old, n=2). Protein expression was analyzed with anti-mouse IL4RA antibody (Biolegend, 144804) and anti-human IL4RA antibody (Biolegend, 355003) by flow cytometry. Mouse IL4RA was only detectable in wild-type C57BL/6 mice. Human IL4RA was exclusively detectable in homozygous B-hIL4/hIL4RA mice, but not in wild-type C57BL/6 mice. 


Analysis of spleen leukocytes cell subpopulations in B-hIL4/hIL4RA mice


from clipboard

from clipboard


Analysis of spleen leukocyte subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hIL4/hIL4RA mice (n=3, 10-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for CD45 population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T, B, NK, Monocyte, DC and macrophage cells in homozygous B-hIL4/hIL4RA  mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL4 and hIL4RA in place of its mouse counterpart does not change the overall development, differentiation or distribution of these cell types in spleen.


Analysis of spleen T cell subpopulations in B-hIL4/hIL4RA mice

from clipboard


Analysis of spleen T cell subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hIL4/hIL4RA mice (n=3, 10-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ T cells were gated for CD3+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8, CD4, and Treg cells in homozygous B-hIL4/hIL4RA mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL4 and hIL4RA in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell sub types in spleen. Values are expressed as mean ± SEM.

Analysis of Lymph node leukocyte subpopulations in B-hIL4/hIL4RA mice

from clipboard


Analysis of subpopulation of leukocytes in lymph node by FACS. Lymph node were isolated from female C57BL/6 and B-hIL4/hIL4RA mice (n=3, 10-week-old). Flow cytometry analysis of the lymph node was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ T cells were used for further analysis as indicated here. B. Results of FACS analysis. Percent of T, B, and NK cells in homozygous B-hIL4/hIL4RA  mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL4 and hIL4RA in place of its mouse counterpart does not change the overall development, differentiation or distribution of these cell types in lymph node. Values are expressed as mean ± SEM.

Analysis of lymph node T cell subpopulations in B-hIL4/hIL4RA mice


from clipboard


Analysis of subpopulation of T cells in lymph node by FACS. Lymph node were isolated from female C57BL/6 and B-hIL4/hIL4RA mice (n=3, 10-week-old). Flow cytometry analysis of the lymph node was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ T cells were used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8, CD4, and Treg cells in homozygous B-hIL4/hIL4RA  mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL4 and hIL4RA in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in lymph node. Values are expressed as mean ± SEM.


Dupilumab significantly inhibited the secretion of IgE induced by hIL4 in B-hIL4/hIL4RA mice



from clipboard


(A) Splenic B cells from C57BL/6 and B-hIL4/hIL4RA mice were cultured with LPS alone or together with 50ng/mL mIL-4/hIL-4. Culture supplements were harvested on day 6 for quantification of IgE by ELISA.(B) Splenic B cells from B-hIL4/hIL4RA mice were incubated with increasing doses of dupilumab (in house) for half of an hour before adding LPS and hIL-4 (50 ng/mL). Culture supernatant was harvested on day 6 for quantification of IgE  by ELISA. The result show that B cells from B-hIL4/hIL4RA mice responded well to LPS and IL-4 with IgE production, as similar to C57BL/6 mice. Dupilumab (in house) could effectively block the expression of IgE.


Dupilumab significantly inhibited the activation of B cells induced by hIL4 in B-hIL4/hIL4RA mice





Analysis of activity of B cells in spleen by FACS. Splenocytes were isolated from B-hIL4/hIL4RA mice and incubated with varying concentrations of IgG4 or dupilumab for half an hour. Adding human IL4 (50 pM) for 72 hours and analyzing the activity of B cells. The dupilumab group showed an effect to block B cell activation in B-hIL4/IL4RA mice and showed a dose-dependent effect; the control hIgG4 did not show an effect on block B cell activation.


In vivo efficacy of anti-human IL4RA antibody with asthma mouse model

from clipboard


The number of BALF immune cells in mouse asthma model


from clipboard

from clipboard


Analysis of immune cells in BALF by FACS. BALF immune cells were isolated from B-hIL4/hIL4RA mice (n=4 or n=5). The number and proportion of eosinophils were analyzed by flow cytometry under the treatment of PBS/dupilumab (in house). After treatment of dupilumab (in house), the number of CD45+ cells and eosinophils were much lower than the positive control in homozygous B-hIL4/hIL4RA mice.


OVA specific and total IgE production in serum and BALF of mouse asthma model


from clipboard


IgE production in serum of mouse asthma model. Serum was collected at the study endpoint. IgE levels responded to OVA-specific antibody and total IgE levels were analyzed. The results show that the levels of IgE in mice treated with dupilumab (in house) is much lower than that in untreated mice.


H&E staining in asthma-like model in B-hIL4/hIL4RA mice


from clipboard

H&E staining of asthma-like model in B-hIL4/hIL4RA mice. Lung tissues were collected at the study endpoint. H&E staining results showed that the lung tissues from B-hIL4/hIL4RA mice exposed to PBS aerosols did not show any inflammation. OVA exposure resulted in a significant increase in peribronchial and perivascular inflammation in B-hIL4/hIL4RA mice. A significant reduction in eosinophils infiltration was observed in mice treated with dupilumab (in house). 


Asthma model introduction


Establishment of asthma mouse model- HDM-induced acute asthma model


Experimental animals:5-6 weeks old, female
Modeling reagent:50 μg HDM in 50 μl PBS (intranasally, i.n.)
Modeling paradigm: 

from clipboard



Efficacy assessment of anti-human IL4RA antibody in mouse asthma model induced  with HDM


from clipboard


The asthma model was induced in B-hIL4/hIL4RA mice using HDM. (A)The number of CD45+ cells in BALF. (B)The number of eosinophils in BALF. (C)The proportion of eosinophils to CD45+ cells. The results showed that after sensitization and challenge with HDM, the leukocyte infiltration of mice in G2 model group was significantly increased compared with G1 control group, and their eosinophil content was significantly increased, suggesting that the model was successfully established. After administration of 25 mg/kg dupilumab (in house), the numbers of CD45 + cells and eosinophils were significantly lower compared with the G2 model group. 

Efficacy assessment of anti-human IL4RA antibody in mouse asthma model induced  with HDM

from clipboard

Detection of IgE levels in serum of asthmatic mouse model. Serum was taken at the end of the experiment and total IgE levels were measured using ELISA in serum. The results showed that the levels of total IgE in G2 model group were significantly increased compared with G1 control group, suggesting successful modeling. Total IgE levels were significantly lower after administration of dupilumab (in house) drug compared with the G2 modeling group.


Experimental schedule for Induction of AD-like skin lesions and in vivo efficacy of anti-human IL4RA antibody  

from clipboard


Experimental schedule for Induction of AD-like skin lesions and in vivo efficacy of anti-human IL4R antibody. OXZ was applied to dorsal and ear skin of mice on day 0, and then challenge to the same  site of skin ten times from days 7 to 26. Anti-human IL4RA antibody dupilumab (in house) was administered by intraperitoneal injection twice a week on days 6 to 23. Serum, ear and dorsal skin were collected at the endpoint on day 26. AD: atopic dermatitis; OXZ: oxazolone.

In vivo efficacy of anti-human IL4RA antibody-Experiment 1 with AD model

from clipboard


Efficacy of anti-human IL4RA antibody in B-hIL4/hIL4RA mice. Mice in each group were treated with different dose of dupilumab produced in house. Doses are shown in legend. (A) Body weight changes during treatment. (B) Statistical analysis of ear thickness in each group. Epidermis of ear began to desquamate from day 18. So the ear thickness was decreased from day 18 as shown in figure. (C) Total IgE levels in serum. Total IgE levels were measured by ELISA on day 26. Ear thickness and concentrations of total serum IgE were negative related with the doses of antibody. (n = 5).

H&E staining of ear skin in atopic dermatitis model of B-hIL4/IL4RA mice

from clipboard


from clipboard


Effects of anti-human IL4RA antibody on inflammatory infiltration in ear skin of the  AD mouse model. (A) Hematoxylin and eosin (H&E) staining. (B) Score of eosinophils infiltrated in ear epidermal skin (n=5). Infiltration scores of eosinophils in ear skin were negatively related to the doses of antibody, demonstrating that the B-hIL4/hIL4RA mice provide a powerful preclinical model for in vivo evaluation of anti-human IL4RA antibodies. Infiltration score of eosinophils: 1=slight; 2=mild; 3=moderate; 4=severe. AD: Atopic dermatitis; ND: Not detectable.

In vivo efficacy of anti-human IL4RA antibody-Experiment 2 with AD model

from clipboard


Efficacy of anti-human IL4RA antibody in B-hIL4/hIL4RA mice. Mice in each group were treated with dupilumab produced in house. Doses are shown in legend. (A) Body weight changes during treatment. (B) Statistical analysis of ear thickness in each group. Epidermis of ear began to desquamate from day 18. So the ear thickness was decreased from day 18 as shown in figure. (C) Total IgE levels in serum. Total IgE levels were measured by ELISA on day 26. Ear thickness and concentrations of total serum IgE were negative related with the doses of antibody. (n = 5).

H&E staining of ear skin in atopic dermatitis model of B-hIL4/IL4RA mice

from clipboard


Effects of anti-human IL4RA antibody on inflammatory infiltration in ear skin of the  AD mouse model. (A) Hematoxylin and eosin (H&E) staining. (B) Score of eosinophils infiltrated in ear epidermal skin (n=5). Infiltration scores of eosinophils in ear skin were significantly reduced after administration of the antibodies, demonstrating that the B-hIL4/hIL4RA mice provide a powerful preclinical model for in vivo evaluation of anti-human IL4RA antibodies. Infiltration score of eosinophils: 1=slight; 2=mild; 3=moderate; 4=severe. AD: Atopic dermatitis; ND: Not detectable.